ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Nereid Therapeutics launches with $50 million series A

by Megha Satyanarayana
November 21, 2020 | APPEARED IN VOLUME 98, ISSUE 45

 

Nereid Therapeutics, in Cambridge, Massachusetts, has received $50 million in series A funding from the venture capital firm Apple Tree Partners. The biotech company wants to develop therapeutics for diseases possibly caused by inappropriate protein activity in biomolecular condensates, which are liquid phases in cells. Nereid’s platform is based on the work of cofounder Clifford Brangwynne of Princeton University.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment